MT-UAVIONIX
8.4.2021 03:37:10 CEST | Business Wire | Press release
Today, uAvionix, the leader in communications, navigation, and surveillance (CNS) solutions for Unmanned Aircraft Systems (UAS), announced ping200X , its flagship Mode S ADS-B OUT Transponder for UAS, has received Technical Standard Order (TSO) certification from the FAA. ping200X is the pinnacle of years of evolution and investment in groundbreaking, low-Size, Weight, and Power (SWaP) avionics developed by uAvionix – certified for use on civil and defense manned and unmanned aircraft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407006039/en/
Weighing only 50 grams, ping200X delivers 200 watts of transmit power while only drawing an average of 1.5 watts from the aircraft's power supply. Its profile enables longer flight times and larger payloads with minimal energy consumption. When paired with truFYX , uAvionix’s SBAS GPS, ping200X meets the requirements of global controlled airspace, delivering safe separation information to Air Traffic Control (ATC), Traffic Collision Avoidance Systems (TCAS), and Detect and Avoid (DAA) systems.
ADS-B and transponder technology is a key component of UAS integration for mixed-use airspace. The FAA’s recent ruling on remote identification for UAVs establishes that Part 21 certificated aircraft must be equipped with a Remote ID device and/or ADS-B OUT Transponder for legal operations. Additionally, the FAA's Concept of Operations for Upper-Class E Traffic Management (ETM) includes ADS-B and Mode S Transponders as key technologies enabling coordination in the upper atmosphere.
ping200X integrates and combines a Mode S Transponder, ADS-B OUT, and an altitude encoder certified to the following TSOs:
- TSO-C112e (Mode S Transponder)
- TSO-C166b (ADS-B OUT Extended Squitter)
- TSO-C88b (altitude encoder)
“Certified avionics ensure the systems perform to the same high standards that have allowed aviation to remain the safest form of transportation for decades,” said Christian Ramsey, President. “This is even more important for systems like transponders and ADS-B which interact with other airspace users. Regulators and ANSPs demand the design assurance and quality assurance that a TSO offers to ensure safe separation of aircraft.”
The ping200X is integrable with many popular onboard UAS autopilots for dynamic control from ground control stations (GCS). ping200X can also be pre-configured before flight and carried as a payload. Replicating the functionality of a cockpit transponder controller, the uAvionix mini-controller allows you to dial-in a squawk code before takeoff for even quicker integration and rapid deployment.
To learn more about ping200X or to request a quote, visit uAvionix.com/products/ping200X/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407006039/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom